Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


instrAction and Protagen form strategic alliance


Dortmund, Germany, March 15, 2011 - instrAction GmbH, Ludwigshafen, the specialist for design and production of selective separation matrices and Protagen AG , Dortmund, a GMP certified service laboratory for protein analysis signed a strategic alliance for the development of customized instrAction ® Phases for downstream processing of biotherapeutics.

“The instrAction® Phases are proprietary synthetic chromatography phases which show excellent performance compared to commonly used matrices for e.g. antibody purification. The unique know-how and expertise of Protagen in GMP-compliant protein analysis and related services will be decisive for the development of a portfolio of new tailor made separation phases for the production of recombinant protein drugs, other biotherapeutics and biosimilars”, comments Dr. Thomas Schwarz, CEO of instrAction.

“In order to exploit the full value of this exciting new protein purification technology and to convince customers from pharma process development and production, it is important to provide convincing data sets from feasibility studies. Protagen has all the tools and know-how to support instrAction on its way to become the leading company in protein separation technology”, underscores Dr. Stefan Müllner, CEO of Protagen.


About Protagen AG - http://www.protagen.de/
Protagen AG is an international leading specialist in the fields of in-vitro diagnostics and GMP-compliant protein analysis. The innovations of Protagen are UNIarray®, a technology platform for the development of novel serum based diagnostics, as well as UNIchip®, a versatile product family of protein microarrays for faster development of antibodies.

About instrAction GmbH - www.instraction.com
instrAction, founded in 1997 and located at the BASF site in Ludwigshafen, develops and manufactures 'instrAction® phases” as novel highly selective resins for chromatography. The proprietary technology enables the immobilization of a wide variety of functional ligands on a polymer network, coated on very different porous backbone materials. Small molecules as well as substances with high molecular weight are separated by highly selective reversible interactions. The high selectivity of an instrAction stationary phase is thereby reached by multivalent-multimodal interactions between target molecule and the functional ligands of the phase, similar to the lock-and-key principle.


Contact
Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: info@protagen.de

Media Enquiries
Bettina Franz
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: bettina.franz@protagen.de


Publisher Contact Information:

Protagen
+49 (0) 231 9742 6300
bettina.franz@protagen.de

Company profile of Instraction GmbH
Past press releases of Instraction GmbH.

Data


20,276
Tech investments
From our Online Data Service
13,080
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Jul 27N/AInternet commerce
Jul 27€55.0MInternet commerce
Jul 24€1.0MBiotechnology
Jul 23€33.0MBiotechnology
Jul 23€37.0MInternet commerce
Jul 22€2.2MBiotechnology
Jul 22N/ABiotechnology

For information on Europe's most extensive database on technology funding click here!

Events


BIO-Europe 2015
November 2 - 4, 2015

CONNECTIONS Europe
November 10 - 11, 2015


Press Releases


Jul 22
Wilson Therapeutics
wilson therapeutics announces the appointment of dr. carl bjartmar ...

Jul 16
Immunocore Ltd
immunocore secures $320 million (£205 million) in europe’s largest ...

Jul 15
Mailjet
iris capital leads series b round for email service provider mailjet

Jul 15
Credit Benchmark
credit benchmark raises $20m in series b financing led by balderton...

Jul 10
Autifony Therapeutics
autifony therapeutics extends series a with £8 million for hearing ...





About usContact usLegal Information
Copyright © 1999-2015
Emerging Technology Research Europe Inc. All rights reserved.